Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...2122232425262728293031...123124»
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Cost-utility analysis of sequential therapy with sorafenib followed by regorafenib versus single-line therapies in advanced hepatocellular carcinoma. (Poster Bd # E16) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_468;    
    We evaluated the lifetime cost-effectiveness of a sequence of treatment with sorafenib followed by regorafenib (SOR-REG) compared with licensed single-line therapies for which there is no clear sequencing options available, including atezolizumab plus bevacizumab (ATEZO+BEV), which has become the standard of care in first-line treatment, as well as lenvatinib (LEN), followed by best supportive care (BSC). A sequence of SOR-REG for patients with advanced HCC is cost-effective at WTP thresholds of
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Novel GPC3-targeting radiopharmaceutical therapy for hepatocellular carcinoma. (Poster Bd # E12) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_464;    
    A sequence of SOR-REG for patients with advanced HCC is cost-effective at WTP thresholds of Preclinical in vitro and in vivo data demonstrate the potential of RAYZ-8009 as a theranostic agent for the treatment of patients with GPC3+ HCC.
  • ||||||||||  Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. (Poster Bd # B14) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_413;    
    A Markov model was built based on five global, multicenter, open-label, phase III randomized trials (Himalaya, IMbrave150, ORIENT-32, CARES-310, LEAP-002) to investigate the cost-effectiveness of tremelimumab plus durvalumab (STRIDE), atezolizumab plus bevacizumab (A+B), sintilimab plus bevacizumab biosimilar (IBI305) (S+B), camrelizumab plus rivoceranib (C+R) and pembrolizumab plus lenvatinib (P+L). As one of the promising immuno-combination therapies in the first-line systemic treatment for unresectable HCC, camrelizumab plus rivoceranib demonstrated the potential to be the most cost-effective strategy, which warranted further studies to best inform the real-world clinical practices.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
    Organ-specific response with first-line atezolizumab-bevacizumab versus lenvatinib for patients with advanced hepatocellular carcinoma. (Poster Bd # B12) -  Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_411;    
    Compared to lenvatinib, atezolizumab-bevacizumab was associated with a favorable organ-specific response regardless of the site of the tumor lesions. Unlike anti-PD-1 monotherapy, atezolizumab-bevacizumab had a comparable organ-specific response between intrahepatic and extrahepatic lesions, especially for those with viral etiology HCCs.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Preclinical, Journal:  Increased c?SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma. (Pubmed Central) -  Nov 29, 2023   
    When co-administering dasatinib, a c-SRC inhibitor, the partial restoration of lenvatinib sensitivity in the JHH-7_LR cell line was observed. The present study demonstrated that increased c-SRC expression was partially associated with HCC resistance to lenvatinib, suggesting that c-SRC inhibition could reduce the resistance of HCC to lenvatinib.
  • ||||||||||  Journal:  Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer. (Pubmed Central) -  Nov 29, 2023   
    In this study, the use of oral VEGFR-TKIs was associated with an increased risk of AAD occurrence. These findings elucidate vascular toxic effects and may provide a substantial reference for reducing the socioeconomic burden of adverse events associated with VEGFR-TKI use.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial completion date, Trial termination, Trial primary completion date, Combination therapy:  Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Nov 29, 2023   
    P1/2,  N=40, Terminated, 
    These findings elucidate vascular toxic effects and may provide a substantial reference for reducing the socioeconomic burden of adverse events associated with VEGFR-TKI use. Trial completion date: Oct 2022 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Aug 2023; Enrollment is over, the study was completed
  • ||||||||||  Trial initiation date:  OPTI-DOSE: OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (clinicaltrials.gov) -  Nov 29, 2023   
    P4,  N=30, Not yet recruiting, 
    Trial completion date: Oct 2022 --> Aug 2023 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Aug 2023; Enrollment is over, the study was completed Initiation date: Sep 2023 --> May 2024